New heart device registry aims to track Real-World results for AFib patients
NCT ID NCT06026345
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This registry will follow 540 people with atrial fibrillation who are treated with the Affera ablation device. Researchers want to see how well the device stops irregular heart rhythms and how safe it is in everyday medical practice. The study is observational, meaning patients get their normal care, and no new treatments are being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beacon Hospital
RECRUITINGDublin, D18 AK68, Ireland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Charité Universitätsmedizin Berlin, DHZC - Campus Charité Mitte
RECRUITINGBerlin, 10117, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clinique Pasteur
RECRUITINGToulouse, 31076, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Haut-Lévêque - CHU de Bordeaux
RECRUITINGBordeaux, 33604, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
IKEM - Institut Klinické a Experimentální Medicíny
RECRUITINGPrague, 14021, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Imperial College Healthcare NHS Trust - Hammersmith Hospital
RECRUITINGLondon, W12 0HS, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Inselspital - Universitätsspital Bern
RECRUITINGBern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MVZ CCB Frankfurt und Main Taunus GbR
RECRUITINGFrankfurt, 60431, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nemocnice Na Homolce
RECRUITINGPrague, 15030, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Papworth Hospital NHS Foundation Trust
RECRUITINGCambridge, CB2 0AY, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitair Ziekenhuis Brussel
RECRUITINGBrussels, 1090, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitäres Herzzentrum
RECRUITINGHamburg, 20246, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Affera Platform (cardiac ablation device)
What this could lead to
If successful, this registry will provide real-world evidence on how well the Affera device controls atrial fibrillation and its safety profile.
What could go wrong
This is an observational registry, not a controlled trial, so results may be influenced by patient selection and lack a comparison group. It cannot prove the device works better than alternatives.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.